The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Michael Baumann - One of the best experts on this subject based on the ideXlab platform.
-
cancer stem cells as a Predictive Factor in radiotherapy
Seminars in Radiation Oncology, 2012Co-Authors: Thomas Brunner, Leoni A Kunzschughart, Philipp Grossegehling, Michael BaumannAbstract:Cancer stem cell research is one of the most thriving and competitive areas in oncology research because it has the potential to dramatically affect clinical outcomes. Led by progress in hematology, cancer stem cell research has now provided evidence to play an important role for solid cancers as well. Because radiotherapy is only second to surgery in terms of its curative potency, it is very important for radiation oncologists to learn whether progress in cancer stem cell biology can enable them to exploit this knowledge to help cure more patients suffering from cancer. The present article gives an overview about the challenges of the cancer stem cell concept and highlights some important phenomena that are under intense investigation, such as phenotypic plasticity of stemness and impact and dynamics of microenvironmental niches. We discuss the potential and limitations of current experimental and theragnostic tools and end up with an agenda for future research as outlook for translational possibilities in the clinic.
Charles Dumontet - One of the best experts on this subject based on the ideXlab platform.
-
The ribonucleotide reductase large subunit (RRM1) as a Predictive Factor in patients with cancer.
The Lancet. Oncology, 2010Co-Authors: Lars Petter Jordheim, Pascal Sève, Olivier Tredan, Charles DumontetAbstract:The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of cell proliferation, cell migration, tumour and metastasis development, and the synthesis of deoxyribonucleotides for DNA synthesis. It is also a cellular target for the chemotherapeutic agent, gemcitabine. RRM1 has been studied in a large number of patients with different types of cancer, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and biliary tract cancer, to establish its prognostic or Predictive value when patients were treated with gemcitabine, and mRNA expression and genetic variants as determined by genotyping have in some cases been associated with clinical outcome of patients with cancer. Here, we review preclinical and clinical studies of RRM1 assessment and discuss the further steps in the development of this clinically pertinent biomarker.
-
is class iii β tubulin a Predictive Factor in patients receiving tubulin binding agents
Lancet Oncology, 2008Co-Authors: P Seve, Charles DumontetAbstract:Summary On the basis of preclinical studies that show overexpression of class III β-tubulin is associated with resistance to tubulin-binding agents, several investigators have addressed the relation between class III β-tubulin and outcome in patients treated with such agents. High expression of class III β-tubulin has been found to be correlated either with low response rates in patients treated with regimens containing taxanes or vinorelbine or with reduced survival in patients with non-small-cell lung cancer, in breast, ovarian, and gastric cancers, and in cancers of unknown primary site. Two studies have shown patients with advanced non-small-cell lung cancer receiving paclitaxel whose tumours expressed high levels of class III β-tubulin had a lower response to paclitaxel and shorter survival, whereas this variable was not found to be Predictive in patients receiving regimens without tubulin-binding agents. Conversely, analysis of samples from patients in the JBR-10 trial, which compared adjuvant chemotherapy to no further therapy in operable non-small-cell lung cancer, showed that chemotherapy seemed to overcome the negative prognostic effect of high levels of expression of class III β-tubulin and the greatest benefit from cisplatin/vinorelbine was seen in patients with high levels of expression of class III β-tubulin. Further analyses in operable and advanced non-small-cell lung cancer showed a relation between high expression of class III β-tubulin and baseline Factors such as age under 60 years, adenocarcinoma and large-cell carcinoma histologies, and advanced stage of disease. These results suggest that class III β-tubulin could be both a prognostic and a Predictive Factor. Large randomised studies are warranted to determine the prognostic or Predictive value of class III β-tubulin in different settings and tumours.
Sebastien Salas - One of the best experts on this subject based on the ideXlab platform.
-
Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
Cancers, 2019Co-Authors: Alexandre Nonneville, Dominique Barbolosi, Maeva Andriantsoa, Raouf El-cheikh, Florence Duffaud, Francois Bertucci, Sebastien SalasAbstract:Introduction: Based on a mathematical model of trabectedin-induced neutropenia, we assessed the Predictive value of absolute neutrophil count (ANC) on progression-free survival (PFS) in an independent validation cohort of patients treated with trabectedin. Methods: We collected data from 87 patients in two expert centers who received at least two cycles of trabectedin for soft tissue sarcomas (STS) treatment. Correlations between ANC, patients' characteristics, and survival were assessed, and a multivariate model including tumor grade, performance status, ANC, and hemoglobin level was developed. Results: Therapeutic ANC >= 7.5 G/L level was associated with shorter PFS: 3.22 months (95% confidence interval (CI), 1.57-4.87) in patients with ANC >= 7.5 G/L vs. 5.78 months (95% CI, 3.95-7.61) in patients with ANC < 7.5 G/L (p = 0.009). Age, primary localization, lung metastases, dose reduction, hemoglobin, and albumin rates were also associated with PFS. In multivariate analysis, ANC >= 7.5 G/L was independently associated with poor PFS and overall survival. Conclusion: We validated increased pre-therapeutic ANC as a Predictive Factor of short PFS in patients starting trabectedin for STS. ANC appears to have an impact on survival rates and may be used as a decision-making tool for personalizing second-line strategies in patients with metastatic STS.
Qixun Chen - One of the best experts on this subject based on the ideXlab platform.
-
the combination of platelet count and neutrophil lymphocyte ratio is a Predictive Factor in patients with esophageal squamous cell carcinoma
Translational Oncology, 2014Co-Authors: Jifeng Feng, Ying Huang, Qixun ChenAbstract:OBJECTIVE: The prognostic value of inflammation indexes in esophageal cancer was not established. In this study, therefore, both prognostic values of Glasgow prognostic score (GPS) and combination of platelet count and neutrophil lymphocyte ratio (COP-NLR) in patients with esophageal squamous cell carcinoma (ESCC) were investigated and compared. METHODS: This retrospective study included 375 patients who underwent esophagectomy for ESCC. The cancer-specific survival (CSS) was calculated by the Kaplan-Meier method, and the difference was assessed by the log-rank test. The GPS was calculated as follows: patients with elevated C-reactive protein (> 10 mg/l) and hypoalbuminemia ( 300 × 109/l) and neutrophil lymphocyte ratio (> 3) were assigned to COP-NLR2. Patients with one or no abnormal value were assigned to COP-NLR1 or COP-NLR0, respectively. RESULTS: The 5-year CSS in patients with GPS0, 1, and 2 was 50.0%, 27.0%, and 12.5%, respectively (P < .001). The 5-year CSS in patients with COP-NLR0, 1, and 2 was 51.8%, 27.0%, and 11.6%, respectively (P < .001). Multivariate analysis showed that both GPS (P = .003) and COP-NLR (P = .003) were significant predictors in such patients. In addition, our study demonstrated a similar hazard ratio (HR) between COP-NLR and GPS (HR = 1.394 vs HR = 1.367). CONCLUSIONS: COP-NLR is an independent Predictive Factor in patients with ESCC. We conclude that COP-NLR predicts survival in ESCC similar to GPS.
-
preoperative platelet lymphocyte ratio plr is superior to neutrophil lymphocyte ratio nlr as a Predictive Factor in patients with esophageal squamous cell carcinoma
World Journal of Surgical Oncology, 2014Co-Authors: Jifeng Feng, Ying Huang, Qixun ChenAbstract:Recent studies have shown that the presence of systemic inflammation correlates with poor survival in various cancers. The aim of this study was to determinate the prognostic value of the neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) in patients with esophageal squamous cell carcinoma (ESCC). Preoperative NLR and PLR were evaluated in 483 patients undergoing esophagectomy for ESCC from January 2005 to December 2008. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods. Receiver operating characteristic (ROC) curves were also plotted to verify the accuracy of NLR and PLR for survival prediction. High preoperative NLR (≥3.5 versus < 3.5, P = 0.039) and PLR (≥150 versus < 150, P < 0.001) were significantly associated with poor overall survival in multivariate analysis. However, our study demonstrated a better discrimination for the PLR in terms of hazard ratio(HR) than the NLR (HR = 1.840 versus HR = 1.339). Patients with NLR ≥3.5 had significantly poorer overall survival compared to NLR <3.5 (35.4% versus 57.7%, P < 0.001). Patients with PLR ≥150 also had significantly poorer overall survival compared to patients with PLR <150 (32.7% versus 63.5%, P < 0.001). The area under the curve (AUC) was 0.658 (95% confidence interval (CI): 0.610 to 0.706, P < 0.001) for NLR and 0.708 (95% CI: 0.662 to 0.754, P < 0.001) for PLR, indicating that PLR was superior to NLR as a Predictive Factor in ESCC. Preoperative NLR and PLR were significant predictors of overall survival in patients with ESCC. However, PLR is superior to NLR as a Predictive Factor in patients with ESCC.
Thomas Brunner - One of the best experts on this subject based on the ideXlab platform.
-
cancer stem cells as a Predictive Factor in radiotherapy
Seminars in Radiation Oncology, 2012Co-Authors: Thomas Brunner, Leoni A Kunzschughart, Philipp Grossegehling, Michael BaumannAbstract:Cancer stem cell research is one of the most thriving and competitive areas in oncology research because it has the potential to dramatically affect clinical outcomes. Led by progress in hematology, cancer stem cell research has now provided evidence to play an important role for solid cancers as well. Because radiotherapy is only second to surgery in terms of its curative potency, it is very important for radiation oncologists to learn whether progress in cancer stem cell biology can enable them to exploit this knowledge to help cure more patients suffering from cancer. The present article gives an overview about the challenges of the cancer stem cell concept and highlights some important phenomena that are under intense investigation, such as phenotypic plasticity of stemness and impact and dynamics of microenvironmental niches. We discuss the potential and limitations of current experimental and theragnostic tools and end up with an agenda for future research as outlook for translational possibilities in the clinic.
